Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dieter Jocham

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
European Urology|August 4, 2007
Words of wisdom. Re: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerDieter Jocham
Aktuelle Urologie|March 22, 2019
Dieter Jocham
Aktuelle Urologie|November 8, 2007
[Editorial comment on Stepp H. et al.: fluorescence diagnosis and photodynamic therapy in urology]Dieter Jocham
Prostate Cancer and Prostatic Diseases|December 24, 2002
IntroductionProfessor Dieter Jocham
Current Opinion in Molecular Therapeutics|February 25, 2003
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/MillenniumChristian Doehn, Dieter Jocham
European Urology|August 4, 2009
Words of wisdom. Re: the efficacy and safety of degarelix: a 12-month, comparative, randomized, open- label, parallel-group phase III study in patients with prostate cancerDieter Jocham, Christian Doehn
European Urology|March 19, 2011
Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trialDieter Jocham, Martin Sommerauer
Nature Clinical Practice. Urology|November 13, 2008
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer?Christian Doehn, Dieter Jocham
Current Opinion in Molecular Therapeutics|November 19, 2002
Technology evaluation: PROSTVAC, TherionChristian Doehn, Dieter Jocham
Aktuelle Urologie|March 22, 2019
[Physician health: What makes us ill? What keeps us healthy?]Jörg Braun, Dieter Jocham
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
European Urology|August 4, 2007
Words of wisdom. Re: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerDieter Jocham
Aktuelle Urologie|March 22, 2019
Dieter Jocham
Aktuelle Urologie|November 8, 2007
[Editorial comment on Stepp H. et al.: fluorescence diagnosis and photodynamic therapy in urology]Dieter Jocham
Prostate Cancer and Prostatic Diseases|December 24, 2002
IntroductionProfessor Dieter Jocham
Current Opinion in Molecular Therapeutics|February 25, 2003
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/MillenniumChristian Doehn, Dieter Jocham
European Urology|August 4, 2009
Words of wisdom. Re: the efficacy and safety of degarelix: a 12-month, comparative, randomized, open- label, parallel-group phase III study in patients with prostate cancerDieter Jocham, Christian Doehn
European Urology|March 19, 2011
Words of wisdom. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trialDieter Jocham, Martin Sommerauer
Nature Clinical Practice. Urology|November 13, 2008
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer?Christian Doehn, Dieter Jocham
Current Opinion in Molecular Therapeutics|November 19, 2002
Technology evaluation: PROSTVAC, TherionChristian Doehn, Dieter Jocham
Aktuelle Urologie|March 22, 2019
[Physician health: What makes us ill? What keeps us healthy?]Jörg Braun, Dieter Jocham
Pageof 7